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Hugo ten Cate1,2Abstract
New oral anticoagulants (NOACs) have been introduced to improve anticoagulant therapy worldwide, but safe
implementation may require additional measures. First, optimization of dose adjustment based on therapeutic
levels of the drug may be more appropriate than fixed dose therapy. The development and implementation in
quantitative laboratory assays will enable further dose optimization. Second, non-adherence to medication is a
potential threat to the safe use of NOACs. Since cardiovascular medication may not be optimally used in about
50% of patients, procedures to improve adherence are imperative, also for NOAC therapy and in particular in elderly
patients.
Keywords: New oral anticoagulants, Adherence, Vitamin K antagonists, Laboratory assaysBackground
Since mid 20th century, vitamin K antagonists (VKA)
have been introduced to become the main type of anti-
coagulant therapy for the prevention and treatment of
thrombotic disorders [1]. From onset, VKA therapy has
been monitored by means of a prothrombin clotting
time, aiming for a certain degree of prolongation. Given
interindividual variation in PT responses, individual
dose adjustment of VKA was warranted. This pro-
thrombin time based laboratory monitoring further
evolved towards a more standardized way of testing,
based on the International Normalized Ratio (INR).
Over the past decades, INR adjusted VKA therapy has
remained the exclusive form of oral anticoagulant ther-
apy [2,3]. Obviously, the requirement of INR dose ad-
justment was felt as a practical burden to both patient
and physician. In particular, in areas of the world where
proper INR management is difficult or even impossible
to achieve, the idea of fixed dose anticoagulation is at-
tractive. Also for this reason, studies were undertaken
addressing the potential value of fixed dose VKA admi-
nistration. Unfortunately, although some of these stud-
ies suggested a potential benefit, the ultimate verdict isCorrespondence: h.tencate@maastrichtuniversity.nl
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reproduction in any medium, provided the ornegative. Fixed dose warfarin failed to demonstrate a
clinically significant antithrombotic effect for diverse in-
dications including atrial fibrillation, myocardial infarc-
tion and catheter related thrombosis [4-10].
New oral anticoagulants (NOACs) have been devel-
oped in order to improve medical treatment of patients
at risk of (recurrence) thrombotic disorders. One of the
principles applied in the clinical testing of NOACs has
been the application of a fixed dose, with some possibil-
ity for dose adjustment based on clinical criteria (renal
function and/or specific interactions) [11]. Subsequent
large scale clinical trials established the efficacy and safety
of fixed doses of dabigatran, rivaroxaban and apixaban,
for preventing ischemic stroke [12-14] and (recurrent)
venous thromboembolism [15-18] as compared to INR
titrated warfarin. This opened the way for registration
of these drugs in the chosen doses for these indications.
Currently, in many countries dabigatran, rivaroxaban
and apixaban are registered for AF and/or prevention
and/or treatment of venous thromboembolism, while
studies with edoxaban are nearing completion. NOACs
are being prescribed in many countries, in part replacing
VKA, although a considerable number of indications for
VKA remain, largely determined by indications not stud-
ied for NOAC’s, and/or by exclusion criteria applied in
the phase 3 trials.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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From a theoretical point of view a fixed dose policy is
remarkable for the class of anticoagulants. In fact, there
are no convincing arguments in favor. In contrast to
most platelet inhibitors, the effect of the NOAC’s is not
irreversible, so there is no all or nothing effect. Kinetic-
ally, one would expect a dose response effect, so that an
optimal drug level should be obtained to obtain the cor-
rect balance between antithrombotic efficacy and bleed-
ing risk (like with VKA). Also, the poor experience with
fixed doses of VKA should not have encouraged efforts
to prove that fixed doses of anticoagulants are ideal.
Several arguments in favor of fixed dosing may also be
given. Overall, indeed, a more predictable and perhaps
more stable pharmacokinetic (PK) profile may be expected
from NOACs as compared to VKA, for various reasons
including lack of food interactions and fewer medication
related interactions. Finally, the clinical trials with NOACs
essentially prove the safety of the fixed dose policy; how-
ever, the question may be valid whether this safety (in
practice) could be further improved taking into account
individual PK?
In PK studies with dabigatran [19-24], rivaroxaban
[25-28] and apixaban [29-31] marked interindividual
variation in drug levels has been observed in healthy
persons, as well as in subjects with liver or renal disease.
PK data obtained in the large clinical trials also show
considerable interindividual variation in drug levels and
activities (measured by clotting tests and/or aXa assay).
Published data show the range in responses to dabigatran
for the indication stroke prevention (150 mg bd), with
average peak and trough levels of 175 and 91 ng/ml
(assayed by TT-Hemoclottest), with 25-75th percentile
(ng/ml) of 117–275 and 61–143 ng/mL, respectively
[32,33]. Mean levels of dabigatran were much higher in
those with major bleeding versus those without bleeding
complications (trough 141 ng/mL, SD 97.7 and 92.4, SD
67.9, respectively, RE-LY data total dabigatran groups).
For rivaroxaban, concentration levels determined by
HPLC on clinical samples have now been released, not
for stroke yet. For VTE treatment and prevention of re-
current VTE at a dose of 20 mg once daily, the average
concentration is 215 ug/L peak (90% predicted interval
22–535 ug/L) and a trough of 32 (6–239 ug/L) [34].
Given these data in relation to clinical trial outcome,
are the tested NOAC doses also the ideal doses? This is
an important question as due to the more predictable
and postulated stable PK, it may be foreseen that pa-
tients that on average respond within the preferred con-
centration range (which has not been defined for the
different compounds) will be well protected at an ac-
ceptable risk of recurrent thromboembolism and bleed-
ing, respectively. The argument here is that the
therapeutic window is wider than for VKA. However,given the marked variation between individuals one must
assume that a significant fraction of patients will be ex-
posed to either too low or too high drug levels. Given the
postulated stability in PK, this means that such subjects
will be consistently exposed to suboptimal drug levels for
the duration of their treatment. This also implicates that
improvement in drug management must be considered,
based on individual drug level determination.
From a registration point of view this is a difficult di-
lemma, as not the drugs, but specific doses of NOACs,
were approved by FDA and EMA. As an example, the
FDA only approved the 150 mg dabigatran dose for AF
stroke prevention [35], whereas in Europe both the 110
and 150 mg doses were approved.
The available recommendations for NOAC dose ad-
justment in specific situations like deteriorating renal
function or interactions (e.g. amiodarone) do not solve
the more fundamental question as to why we would not
try to give the optimal dose of a drug to the individual
patient in the first place, potentially further improving
the clinical efficacy risk profile. The fact that warfarin
needs dose adjustment by INR does not disqualify this
agent in itself; it is a matter of inconvenience, but trying
to optimize drug levels within individual patients re-
mains a useful aim. The advantage for NOAC’s may be
that after initial dose optimization based on drug levels,
this may be maintained without further adjustments for
a prolonged period, assuming renal function stability.
Where to go?
Follow up and testing
The clinical community is still trying hard to manage
the NOACs by developing protocols for dose adjust-
ment, indications for testing, dealing with bleeding epi-
sodes and so. Forced by publicity and pharmaceutical
pressure, clinicians and patients need to figure out how
to proceed in practice with drugs that do not require
any monitoring, except for an occasional check on ad-
herence by the pharmacist and a regular renal function
check (although this may not be the ideal management).
In our country the entire follow up of patients on
NOACs (reimbursed only for AF at this stage) is put in
the hands of community pharmacists and general practi-
tioners (and/or nursing home specialists) [36]. Since car-
diologists will not keep the majority of AF patients
under regular surveillance, unless there are complicating
factors, the patient may lack proper surveillance with re-
gard to side effects, complications, adherence etcetera.
This situation is disturbing given the fact that long term
medication is prone not to be used properly by ± 50% of
the patients! [37-39] While there are many ways by
which adherence to medication can be beneficially
influenced this has not yet been an issue of general con-
cern with the NOACs.
ten Cate Thrombosis Journal 2013, 11:8 Page 3 of 5
http://www.thrombosisjournal.com/content/11/1/8Knowing the facts however about non-adherence for
cardiovascular medication (and why would this be differ-
ent for anticoagulation?), what can be done to optimize
the situation? Of course, the absence of laboratory test
burden is a relief for the doctor and patient alike. How-
ever, current recommendations of renal control 2–3
times/year already indicate that one cannot fare well
without any testing [36]. In addition, as stated by some
authors there are many conditions where temporary de-
terioration in renal function may occur in the elderly,
for instance during intercurrent illnesses with diarrhea
[40]. Here, the lessons from VKA therapy should warn
us that any form of comorbidity may have serious conse-
quences for drug intake, absorption and metabolism, in
general, certainly in the elderly.
Current recommendations for laboratory testing aimed
at measuring drug levels or the anticoagulant responses
of NOAC’s are focused on the patients that either
undergo interventions and/or have bleeding complica-
tions. At the same time the list of potential indications
for testing can be easily expanded [40], such that in the
average 75+ patient, 5–10 lab tests per year may be
warranted. Hence, the advantage of being “unmonitored”
while on NOAC’s may only be correct for the relative
healthy, young patient with AF (or VTE), but it is prone
to fail in the elderly.
Meanwhile, many laboratories throughout the world
are actively arranging laboratory assays to become avail-
able. These comprise routine assays like aPTT and PT,
provided reagents are sensitive to detect the effects of
NOAC’s [41,42]. For quantitative purposes several assays
are commercially available, including a modified throm-
bin clotting time for dabigatran and anti-Xa based assays
for FXa inhibitors. Using specific calibrators therapeutic
levels of NOACs can thus be measured. While point of
care assays are particularly wanted for emergency set-
tings, quantitative assays may find a place for eventual
dose adjustment purposes. The idea of implementing la-
boratory testing for NOACs on a routine basis is cur-
rently not useful, in the absence of therapeutic target
levels (and because specific dose regimens instead of
variable doses, have been registered).
Adherence to NOAC’s?
Amazingly little literature is available regarding adher-
ence to anticoagulant therapy. While there is an array of
published reports and expert committee discussion pa-
pers on non-adherence of medication (as summarized in
37–39), particularly for the long term, there is no data-
base on anticoagulants. Apparently, the general percep-
tion is that VKA monitoring with INR provides a tool
for maintaining patients adherent. On the other hand, it
is commonly known that adherence cannot be forced on
persons by single measurements. A good example is theso-called white coat adherence of patients to antihyper-
tensive drugs (summarized in the recent think-tank
paper, 38). A time window of about 5 days before and
after the blood pressure reading conveys a short-term
adherence effect [38]. In analogy with blood pressure
monitoring, more sustainable forms of adherence stimu-
lation are required, also in current patients on VKA
therapy.
Consensus is that with CV medication for chronic use
the non-adherence rate adds up to 50%, translating to
about 125.000 deaths in the USA annually [37,38]. The
total costs of non-adherence range between 100 and 300
billion US$ per year. It has also been estimated that with
every extra dollar spent on adherence enhancing mea-
sures an average of about 4–7 US$ is saved in preventing
major complications and death in diseases including dia-
betes, hypertension and hypercholesterolemia [37,38].
Many individual factors determine adherence and over-
all, there are no major differences in these factors per
type of indication or population. Motivation to take
medication is for one determined by the perception of
symptoms. In case of hypertension, patients are more
motivated to continue medication if they perceive a cer-
tain benefit (reduced headache, less palpitations etc.).
However, in the absence of such symptoms, adherence
drops and this may occur with NOAC therapy, where
(possibly with the exception of the acute phase of VTE),
symptoms are absent (most apparently in AF patients).
Thus, it can be expected that in the management of
NOAC’s non-adherence may reach comparable figures
(±50%) if no measures to boost adherence are being
taken. The argument that in trials fixed dose therapy
was as good as monitored warfarin does not take into
account that trial patients are motivated, literate and get
frequent follow up attention by trial nurses about any
side effects etcetera. Moreover, potentially non-adherent
patients were excluded, at least in some trials. Hence,
these trial data are unlikely to predict real world
adherence.
While NOAC’s are being prescribed worldwide it is
uncertain whether accurate data on complications due
to non-adherence will be recorded. Although major
bleeding complications have been noted and debated
publicly, the absence of the comparison with VKA users
in real life makes sensible conclusions virtually impos-
sible. This is even more so with thromboembolic com-
plications. It is therefore highly unlikely that changes in
incidence of stroke and/or bleeding will raise suspicion
if occurring in patients that are at high risk for such
complications to begin with. Thus, it does not make
sense to wait for complications to raise awareness re-
garding the above issues.
What should be done? For a start, adherence should
become a major topic of discussion, as it has been in the
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use, policy makers, consumers, physicians and insurers
should take their responsibility and start discussing the
options for maximizing adherence, preferably in a pa-
tient centered manner. Solutions may not be simple, but
this should not prevent searching for the best strategies.Concluding remarks
NOACs have been introduced to improve anticoagulant
therapy worldwide. In particular in countries where
current VKA control is difficult to organize, NOACs may
provide a promising alternative. Two issues need to be
taken into account in order to obtain safe anticoagulation
with NOACs (or VKA). First, for NOACs therapeutic
ranges of each agent should become available based on
concentrations and/or dose response effects in laboratory
tests. This will ultimately provide a means of optimizing
dose adjustment in individual patients, more so than by
current algorithms.
Secondly, stimulation of adherence is of utmost im-
portance. Given the body of data showing poor adher-
ence in patients on long term medication, similar
problems may be expected in those using NOACs. This
requires measures to prevent non-adherence, preferably
in a patient centered manner. Further discussion and
studies are needed to raise awareness for this adherence
to medication problem, amongst patients, authorities
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